Get the Stockscreener App
10.12
9.93%
-1.115
After Hours:
10.50
0.385
+3.81%
Tandem Diabetes Care Inc stock is traded at $10.12, with a volume of 3.12M.
It is down -9.93% in the last 24 hours and down -35.12% over the past month.
Tandem Diabetes designs, manufactures, and markets durable insulin pumps for diabetes patients. The firm first entered this market in 2012 and has since introduced multiple generations of pumps leading to its current t:slim X2 device. The firm recently launched its smaller Mobi pump and continues to work on a tubeless patch pump. Nearly three-quarters of total revenue is derived from the US, with the remainder primarily from other developed nations. The pumps themselves generate just over half of total sales, and another one third is from disposable infusion sets that need to be changed over every 2 to 3 days.
See More
Previous Close:
$11.23
Open:
$11.11
24h Volume:
3.12M
Relative Volume:
1.73
Market Cap:
$683.47M
Revenue:
$796.00M
Net Income/Loss:
$-136.49M
P/E Ratio:
-4.8397
EPS:
-2.09
Net Cash Flow:
$-64.24M
1W Performance:
-34.40%
1M Performance:
-35.12%
6M Performance:
-69.82%
1Y Performance:
-73.03%
1-Day Range:
$10.00
$11.12
1-Week Range:
$9.98
$15.54
52-Week Range:
$9.98
$47.60
Tandem Diabetes Care Inc Stock (TNDM) Company Profile
Name
Tandem Diabetes Care Inc
Sector
Industry
Phone
858-366-6900
Address
12400 HIGH BLUFF DRIVE, San Diego, CA
Compare TNDM with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TNDM
Tandem Diabetes Care Inc
|
10.12 | 758.81M | 796.00M | -136.49M | -64.24M | -2.09 |
|
ABT
Abbott Laboratories
|
131.36 | 233.71B | 43.11B | 13.98B | 6.78B | 7.98 |
|
BSX
Boston Scientific Corp
|
102.75 | 152.83B | 18.49B | 2.51B | 3.23B | 1.68 |
|
SYK
Stryker Corp
|
376.67 | 144.35B | 23.82B | 2.92B | 4.02B | 7.55 |
|
MDT
Medtronic Plc
|
92.74 | 119.00B | 33.54B | 4.66B | 5.19B | 3.62 |
|
EW
Edwards Lifesciences Corp
|
78.16 | 46.00B | 5.69B | 4.14B | 577.90M | 6.96 |
Tandem Diabetes Care Inc Stock (TNDM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-07-25 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jul-09-25 | Downgrade | Citigroup | Neutral → Sell |
| Jun-16-25 | Initiated | Truist | Hold |
| Apr-10-25 | Initiated | Mizuho | Neutral |
| Mar-05-25 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Mar-04-25 | Downgrade | Citigroup | Buy → Neutral |
| Mar-03-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Feb-28-25 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Dec-02-24 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Nov-06-24 | Initiated | Bernstein | Outperform |
| Oct-04-24 | Initiated | Goldman | Neutral |
| Oct-02-24 | Initiated | RBC Capital Mkts | Outperform |
| Aug-22-24 | Initiated | Morgan Stanley | Equal-Weight |
| Aug-08-24 | Initiated | Canaccord Genuity | Buy |
| May-30-24 | Initiated | Redburn Atlantic | Buy |
| May-22-24 | Upgrade | Citigroup | Neutral → Buy |
| Apr-29-24 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Apr-25-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Mar-26-24 | Upgrade | Stifel | Hold → Buy |
| Aug-04-23 | Downgrade | Citigroup | Buy → Neutral |
| May-05-23 | Downgrade | BofA Securities | Neutral → Underperform |
| Apr-24-23 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Mar-29-23 | Initiated | UBS | Neutral |
| Jan-26-23 | Initiated | Wolfe Research | Peer Perform |
| Nov-15-22 | Upgrade | Wells Fargo | Underweight → Equal Weight |
| Oct-18-22 | Initiated | Barclays | Overweight |
| Oct-12-22 | Initiated | Jefferies | Buy |
| Aug-09-22 | Downgrade | Wells Fargo | Overweight → Underweight |
| Mar-02-22 | Resumed | BofA Securities | Neutral |
| Jan-19-22 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Jul-21-21 | Resumed | Cowen | Outperform |
| May-25-21 | Initiated | Barclays | Underweight |
| Dec-15-20 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Aug-20-20 | Initiated | Wells Fargo | Overweight |
| Jul-31-20 | Upgrade | Guggenheim | Neutral → Buy |
| Jul-06-20 | Upgrade | Citigroup | Neutral → Buy |
| Jun-18-20 | Reiterated | Raymond James | Outperform |
| Apr-24-20 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Mar-23-20 | Downgrade | Guggenheim | Buy → Neutral |
| Mar-05-20 | Initiated | Citigroup | Neutral |
| Feb-06-20 | Initiated | Raymond James | Outperform |
| Feb-04-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Oct-18-19 | Initiated | Guggenheim | Buy |
| Oct-04-19 | Upgrade | UBS | Neutral → Buy |
| May-17-19 | Reiterated | BofA/Merrill | Neutral |
| May-13-19 | Initiated | SVB Leerink | Outperform |
| Mar-08-19 | Initiated | BMO Capital Markets | Outperform |
| Mar-05-19 | Reiterated | BofA/Merrill | Neutral |
| Feb-27-19 | Reiterated | Lake Street | Buy |
| Nov-21-18 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Sep-26-18 | Reiterated | Dougherty & Company | Buy |
| Sep-26-18 | Reiterated | Piper Jaffray | Overweight |
View All
Tandem Diabetes Care Inc Stock (TNDM) Latest News
Tandem Diabetes Care's 2025 Q2 Earnings Call: Unpacking Contradictions in CMS Proposals, Pharmacy Strategies, and Renewal Growth - AInvest
CFRA slashes Tandem Diabetes Care stock price target on GLP-1 risks - Investing.com Canada
Tandem Diabetes Care: Pioneering the Future of Diabetes Management and a High-Conviction Growth Play in 2025 - AInvest
Top 3 Health Care Stocks That Are Preparing To Pump This Month - Benzinga
TNDM Stock Falls on Q2 Earnings Miss, Revenues Beat, Gross Margin Up - TradingView
Tandem Diabetes Care Inc. Forms Bullish Flag — Upside AheadScalable Portfolio Growth Suggestions Released - metal.it
Tandem Diabetes Care (TNDM) Reports Q2 Earnings: What Key Metrics Have to Say - MSN
Tandem Diabetes projects $1B sales for 2025 as international growth, pharmacy channel, and product innovation drive outlook - MSN
Tandem Diabetes Care: Earnings Miss Confirms Bear CaseDowngrade To Sell (NASDAQ:TNDM) - Seeking Alpha
Insulin pump makers Tandem and Insulet post contrasting Q2 results - MSN
What does recent volatility data suggest for Tandem Diabetes Care Inc.Technical Analysis of Growth Stock Opportunities - Newser
Medtech Executives Monitor CMS Payment Proposal for Diabetes Technology - AInvest
How to build a custom watchlist for Tandem Diabetes Care Inc.Buy Zone Strategy with Pattern Recognition - Newser
Will Tandem Diabetes Care Inc. outperform the marketSmart Trend Analysis With Buy Point Cues - Newser
Chart based exit strategy for Tandem Diabetes Care Inc.Free Trade Ready Stock Watch for Short Term - Newser
How high can Tandem Diabetes Care Inc. stock goReal Time Screener for Growth Trades - Newser
Tandem Diabetes Care Inc. stock retracement – recovery analysisSafe Momentum Strategy With Trend Analysis - Newser
Tandem downgraded to Neutral at Piper Sandler on softer outlook - MSN
Tandem Diabetes Care Inc.’s volatility index tracking explainedWatchlist Summary for Active Day Traders - Newser
Tandem Diabetes Care issues voluntary correction for insulin pumps - Medical Buyer
Tandem Diabetes Care shares rise 4.31% intraday after UBS adjusts price target to $17. - AInvest
Tandem, Insulet monitoring CMS payment proposal for diabetes tech - MedTech Dive
Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Q2 2025 Earnings Call Transcript - Insider Monkey
Positive Outlook for Tandem Diabetes Care: Buy Rating Reaffirmed Amid Growth Catalysts and Strategic Opportunities - TipRanks
Tandem Diabetes Care’s Earnings Call Highlights Growth and Challenges - TipRanks
Insulet Peer Tandem Diabetes Underwhelming Earnings, Dull Outlook Drags Stock - AOL.com
Tandem Diabetes Care Gains FDA Clearance for SteadiSet - TipRanks
Tandem Diabetes Care, Inc. (TNDM) Reports Q2 Loss, Beats Revenue Estimates - MSN
Tandem Diabetes Care (TNDM.O) Sees Sharp Intraday Decline: What’s Behind the Move? - AInvest
Tandem Diabetes Care issues voluntary device correction for certain insulin pumps - Reuters
Tandem insulin pump malfunction linked to 59 injuries - MedTech Dive
Tandem Diabetes' Stalled Momentum: Is the Market Overestimating Long-Term Resilience? - AInvest
TNDM.O Crashes 24.5%: What’s Behind the Sharp Drop? - AInvest
Tandem Diabetes Care price target lowered to $20 at TD Cowen on US sales concerns - Investing.com Canada
Tandem Diabetes announces medical device correction for t:slim X2 insulin pumps - TipRanks
TNDM.O Plummets 25%—What’s Behind the Sharp Move? - AInvest
UBS Adjusts Price Target on Tandem Diabetes Care to $17 From $20, Maintains Neutral Rating - MarketScreener
Earnings call transcript: Tandem Diabetes Care Q2 2025 misses EPS expectations - Investing.com Nigeria
Tandem Diabetes Care hits 7-year low on issuing voluntary device correction for certain insulin pumps - TradingView
Tandem Diabetes Plunges 21.2%: Can a Speaker Glitch Spell the End of a Diabetes Tech Giant? - AInvest
Truist Cuts Price Target on Tandem Diabetes Care to $14 From $15, Keeps Hold Rating - MarketScreener
Tandem Diabetes Issues Correction for Certain t:slim X2 Insulin Pumps - Medical Product Outsourcing
Tandem Diabetes Care drops after issuing voluntary device correction for certain insulin pumps - TradingView
Tandem Diabetes Care Inc issues voluntary medical device correction for select T:slim X2 insulin pumps - MarketScreener
Tandem Diabetes Care Issues Voluntary Medical Device Correction for Select t:slim X2 Insulin Pumps | TNDM Stock News - GuruFocus
Tandem Diabetes Care Issues Voluntary Medical Device Correction for Select t:slim X2 Insulin Pumps - Yahoo Finance
Redwire Posts Downbeat Q2 Results, Joins Tandem Diabetes Care, Fortinet, Symbotic And Other Big Stocks Moving Lower In Thursday's Pre-Market Session - Benzinga
Tandem Diabetes shares fall 18.97% premarket after Q2 sales miss expectations. - AInvest
Tandem Diabetes Care Q2 2025: Revenue Surges but Profitability Concerns PersistNews and Statistics - IndexBox
Tandem Diabetes downgraded to Neutral from Overweight at Piper Sandler - TipRanks
Tandem Diabetes Care Hits Sales Milestone But Stays In The Red - Finimize
Tandem Diabetes Care Inc Stock (TNDM) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.74%
1.39%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):